UA92181C2 - Производные пиримидина и их применение в терапии и в производстве лекарственного средства для предотвращения и/или лечения болезни альцгеймера - Google Patents

Производные пиримидина и их применение в терапии и в производстве лекарственного средства для предотвращения и/или лечения болезни альцгеймера

Info

Publication number
UA92181C2
UA92181C2 UAA200802783A UAA200802783A UA92181C2 UA 92181 C2 UA92181 C2 UA 92181C2 UA A200802783 A UAA200802783 A UA A200802783A UA A200802783 A UAA200802783 A UA A200802783A UA 92181 C2 UA92181 C2 UA 92181C2
Authority
UA
Ukraine
Prior art keywords
pyrimidine derivatives
dementia
treatment
medicament
therapy
Prior art date
Application number
UAA200802783A
Other languages
English (en)
Ukrainian (uk)
Inventor
Ларс Андерссон
Эрван Арзель
Стефан Берг
Джереми Берроуз
Свен Геллберг
Фернандо Уэрта
Торбен Педерсен
Тобиас Рейн
Дидье Роттичи
Карин Стааф
Доминика Турек
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of UA92181C2 publication Critical patent/UA92181C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

Данное изобретение касается применения соединения формулы (И) в виде свободной основы или ее фармацевтически приемлемой соли, сольвата или сольвата такой соли, способа их получения и новых промежуточных соединений, которые в нем используются, как фармацевтических ингредиентов для лечения деменции, болезни Альцгеймера, болезни Паркинсона, лобно-височной деменции типа Паркинсона, комплекса острова Гуам деменции - паркинсонизма, ВИЧ деменции, заболеваний, ассоциированных с патологиями нейрофибрилярных клубков, и/или деменции боксеров.
UAA200802783A 2005-10-03 2006-10-02 Производные пиримидина и их применение в терапии и в производстве лекарственного средства для предотвращения и/или лечения болезни альцгеймера UA92181C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0502174 2005-10-03

Publications (1)

Publication Number Publication Date
UA92181C2 true UA92181C2 (ru) 2010-10-11

Family

ID=37906403

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200802783A UA92181C2 (ru) 2005-10-03 2006-10-02 Производные пиримидина и их применение в терапии и в производстве лекарственного средства для предотвращения и/или лечения болезни альцгеймера

Country Status (20)

Country Link
US (1) US20090105252A1 (ru)
EP (1) EP1945628A4 (ru)
JP (1) JP2009513575A (ru)
KR (1) KR20080059423A (ru)
CN (1) CN101326179A (ru)
AR (1) AR058073A1 (ru)
AU (2) AU2006297890B2 (ru)
BR (1) BRPI0616658A2 (ru)
CA (1) CA2624875A1 (ru)
EC (1) ECSP088405A (ru)
IL (1) IL190150A0 (ru)
NO (1) NO20082067L (ru)
NZ (2) NZ591316A (ru)
RU (2) RU2433128C2 (ru)
SG (1) SG166125A1 (ru)
TW (1) TW200800957A (ru)
UA (1) UA92181C2 (ru)
UY (1) UY29827A1 (ru)
WO (1) WO2007040440A1 (ru)
ZA (1) ZA200802897B (ru)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200811169A (en) * 2006-05-26 2008-03-01 Astrazeneca Ab Chemical compounds
TW200815417A (en) * 2006-06-27 2008-04-01 Astrazeneca Ab New compounds II
TW200815418A (en) * 2006-06-27 2008-04-01 Astrazeneca Ab New compounds I
WO2009017455A1 (en) * 2007-07-30 2009-02-05 Astrazeneca Ab A new combination of (a) an alpha-4-beta-2 -neuronal nicotinic agonist and (b) a gsk3 inhibitor
WO2009017454A1 (en) * 2007-07-30 2009-02-05 Astrazeneca Ab New therapeutic combination of a gsk3 inhibitor and an a7-nicotinic agonist 960
WO2009017453A1 (en) * 2007-07-30 2009-02-05 Astrazeneca Ab New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958
CA2728228A1 (en) 2008-07-14 2010-01-21 Gilead Sciences, Inc. Oxindolyl inhibitor compounds
AU2009271003A1 (en) 2008-07-14 2010-01-21 Gilead Sciences, Inc. Imidazolylpyrimidine compounds as HDAC and/or CDK inhibitors
EP2303881A2 (en) 2008-07-14 2011-04-06 Gilead Sciences, Inc. Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases
NZ590747A (en) 2008-07-28 2012-11-30 Gilead Sciences Inc Cycloalkylidene and heterocycloalkylidene hdac inhibitor compounds
PE20110843A1 (es) * 2008-09-22 2011-12-08 Cayman Chem Co Derivados de 5-(1h-imidazol-5-il)-2-fenilpirimidina, como inhibidores de prostaglandina d sintasa hematopoyetica
UY32562A (es) 2009-04-15 2010-11-30 Astrazeneca Ab Pirimidinas sustituidas por imidazol 724
GB0908772D0 (en) * 2009-05-21 2009-07-01 Astrazeneca Ab New salts 756
KR20120031170A (ko) 2009-06-08 2012-03-30 길리애드 사이언시즈, 인코포레이티드 알카노일아미노 벤즈아미드 아닐린 ｈｄａｃ 저해제 화합물
WO2010144378A2 (en) 2009-06-08 2010-12-16 Gilead Colorado, Inc. Cycloalkylcarbamate benzamide aniline hdac inhibitor compounds
WO2012050517A1 (en) * 2010-10-14 2012-04-19 Astrazeneca Ab Imidazole substituted pyrimidine having a high gsk3 inhibiting potency as well as pan-kinase selectivity
CZ305457B6 (cs) 2011-02-28 2015-09-30 Ústav organické chemie a biochemie, Akademie věd ČR v. v. i. Pyrimidinové sloučeniny inhibující tvorbu oxidu dusnatého a prostaglandinu E2, způsob výroby a použití
EP3741375A1 (en) 2014-07-17 2020-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for treating neuromuscular junction-related diseases
WO2016207366A1 (en) 2015-06-26 2016-12-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of viral infections
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
EP4129994A4 (en) * 2020-03-23 2024-04-24 Whan In Pharmaceutical Co Ltd NOVEL PYRIMIDINE DERIVATIVE AND COMPOSITION FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASES AND CANCER THEREOF
KR102342803B1 (ko) * 2020-03-23 2021-12-24 환인제약 주식회사 신규한 피리미딘 유도체 및 이를 포함하는 신경퇴행성 질환 및 암의 예방 또는 치료용 조성물
WO2022089497A1 (zh) * 2020-10-29 2022-05-05 苏州亚宝药物研发有限公司 取代的二芳基胺化合物及其药物组合物、制备方法和用途
AU2022267249A1 (en) * 2021-04-28 2023-11-02 Cornell University Soluble adenylyl cyclase (sac) inhibitors and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3530710A1 (de) 1985-08-28 1987-03-05 Hoechst Ag Verfahren zur herstellung von halogenphenyl-oxethyl-sulfiden und deren oxidationsprodukten
GB0021726D0 (en) * 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
SE0100569D0 (sv) * 2001-02-20 2001-02-20 Astrazeneca Ab New compounds
JP4309657B2 (ja) * 2001-02-20 2009-08-05 アストラゼネカ・アクチエボラーグ Ｇｓｋ−３関連障害の治療のための２−アリルアミノ−ピリミジン
SE0102439D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
EP1448556A1 (en) * 2001-11-01 2004-08-25 Janssen Pharmaceutica N.V. Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors)
GB0205693D0 (en) * 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
WO2003076434A1 (en) * 2002-03-09 2003-09-18 Astrazeneca Ab 4- imidazolyl substuited pyrimidine derivatives with cdk inhibitiory activity
JP4570955B2 (ja) * 2002-07-09 2010-10-27 バーテクス ファーマスーティカルズ インコーポレイテッド プロテインキナーゼ阻害活性を持つイミダゾール類
GB0226583D0 (en) * 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
GB0229581D0 (en) * 2002-12-19 2003-01-22 Cyclacel Ltd Use
US7407962B2 (en) * 2003-02-07 2008-08-05 Vertex Pharmaceuticals Incorporated Heteroaryl compounds useful as inhibitors or protein kinases
AU2004221881A1 (en) * 2003-03-13 2004-09-30 Vertex Pharmaceuticals Incorporated Compositions useful as protein kinase inhibitors
GB0311276D0 (en) * 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
EP1648887A1 (en) * 2003-07-30 2006-04-26 Cyclacel Limited Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors
TW200528101A (en) * 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
US7132651B2 (en) 2004-04-23 2006-11-07 Framatome Anp, Inc. In-situ BWR and PWR CRUD flake analysis method and tool
US20080280906A1 (en) * 2005-07-30 2008-11-13 David Andrews Imidazolyl-Pyrimidine Compounds for Use in the Treatment of Proliferative Disorders
TW200815418A (en) * 2006-06-27 2008-04-01 Astrazeneca Ab New compounds I
UY32562A (es) * 2009-04-15 2010-11-30 Astrazeneca Ab Pirimidinas sustituidas por imidazol 724

Also Published As

Publication number Publication date
CN101326179A (zh) 2008-12-17
JP2009513575A (ja) 2009-04-02
RU2433128C2 (ru) 2011-11-10
IL190150A0 (en) 2008-08-07
US20090105252A1 (en) 2009-04-23
AR058073A1 (es) 2008-01-23
CA2624875A1 (en) 2007-04-12
SG166125A1 (en) 2010-11-29
NZ566804A (en) 2011-03-31
TW200800957A (en) 2008-01-01
ZA200802897B (en) 2008-12-31
KR20080059423A (ko) 2008-06-27
NO20082067L (no) 2008-07-02
UY29827A1 (es) 2007-05-31
BRPI0616658A2 (pt) 2011-06-28
AU2006297890B2 (en) 2011-04-28
EP1945628A4 (en) 2010-06-02
WO2007040440A1 (en) 2007-04-12
EP1945628A1 (en) 2008-07-23
RU2008110910A (ru) 2009-11-10
AU2006297890A1 (en) 2007-04-12
NZ591316A (en) 2012-06-29
ECSP088405A (es) 2008-05-30
AU2011200948A1 (en) 2011-03-24
RU2011115406A (ru) 2012-10-27

Similar Documents

Publication Publication Date Title
UA92181C2 (ru) Производные пиримидина и их применение в терапии и в производстве лекарственного средства для предотвращения и/или лечения болезни альцгеймера
TW200736223A (en) N-(pyridin-2-yl)-sulfonamide derivatives
TW200745111A (en) New compounds
TW200606164A (en) New compounds
DE60318193D1 (en) Phenethanolaminderivate
WO2008002244A8 (en) Imidazol-pyrimidine derivatives for treatment of diseases related to glycogen synthase kinase (gsk3)
AU2002359164A8 (en) Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
HK1157337A1 (ru)
DK1689721T3 (da) Aminopyrazolderivater som GSK-3-ihibitorer
CY1115484T1 (el) Ενωσεις, συνθεσεις και μεθοδοι για την θεραπεια αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων, οπως νοσος alzheimer, διαβητης τυπου 2 και νοσος parkinson
DE60315492D1 (de) Medizinisch verwendbare arylethanolamin verbindungen
WO2008002245A3 (en) Imidazol-pyrimidine derivatives for treatment of diseases related to glycogen synthase kinase (gsk3)
TW200621762A (en) Novel compounds
PL1687305T3 (pl) Pochodne 1H-imidazochinolin jako inhibitory kinaz białkowych
SG137850A1 (en) Substituted n-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies
TW200800984A (en) New compounds
MX2009010165A (es) Nuevas imidazo[4,5-b]piridina-7-carboxamidas 704.
WO2005037798A3 (en) Amide or thiomide derivatives and their use in the treatment of pain
MY135218A (en) 2,6-quinolinyl and 2,6-naphthyl derivatives and their use in the treatment of vla-4 dependent diseases
TW200639156A (en) New compounds
DK1641454T3 (da) Pyrazolo[3,4-B]pyridin-6-oner som GSK-3-hæmmere
AU2002359162A1 (en) Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
MXPA05013628A (es) Pirazolo[3,4-b]piridin-6-onas como inhibidores de gsk-3.
AU2020278236A8 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
TW200640465A (en) New pharmaceutically active compounds for the treatment of respiratory diseases